ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near New Haven, CT, USA:

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)

New Haven, Connecticut, United States and 211 other locations

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 2

Celgene
Celgene

Stamford, Connecticut, United States and 48 other locations

escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: CC-93269

Phase 1

Celgene
Celgene

New Haven, Connecticut, United States and 34 other locations

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

New Haven, Connecticut, United States and 256 other locations

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Enrolling
Relapsed and/or Refractory Multiple Myeloma
Drug: Cyclophosphamide
Drug: Fludarabine

Phase 1

Juno Therapeutics

New Haven, Connecticut, United States and 17 other locations

Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic ma ...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin frozen liquid
Drug: Belantamab mafodotin lyophilized powder

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

New Haven, Connecticut, United States and 58 other locations

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone...

Active, not recruiting
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

Phase 2

Amgen
Amgen

New Haven, Connecticut, United States and 45 other locations

This is a study to test the safety and effectiveness of the study drug, daratumumab in combination with carfilzomib, lenalidomide and dexamethasone....

Active, not recruiting
Multiple Myeloma
Drug: daratumumab
Drug: lenalidomide

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

Phase 3

Pfizer
Pfizer

Commack, New York, United States and 262 other locations

after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have alre...

Enrolling
Multiple Myeloma
Drug: Talquetamab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems